- Home
- TCRX
as of 01-22-2026 12:19pm EST
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 64.1M | IPO Year: | 2021 |
| Target Price: | $8.50 | AVG Volume (30 days): | 554.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.88 - $2.67 | Next Earning Date: | 03-04-2026 |
| Revenue: | $8,423,000 | Revenue Growth: | -10.03% |
| Revenue Growth (this year): | 286.83% | Revenue Growth (next year): | -26.26% |
AI-Powered TCRX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of TScan Therapeutics Inc. (TCRX)
10% Owner
Avg Cost/Share
$0.90
Shares
6,232
Total Value
$5,601.94
Owned After
8,019,148
SEC Form 4
10% Owner
Avg Cost/Share
$0.90
Shares
75,500
Total Value
$67,950.00
Owned After
8,019,148
SEC Form 4
10% Owner
Avg Cost/Share
$0.90
Shares
80,069
Total Value
$71,974.02
Owned After
8,019,148
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | TCRX | 10% Owner | Dec 23, 2025 | Buy | $0.90 | 6,232 | $5,601.94 | 8,019,148 | |
| Lynx1 Capital Management LP | TCRX | 10% Owner | Dec 22, 2025 | Buy | $0.90 | 75,500 | $67,950.00 | 8,019,148 | |
| Lynx1 Capital Management LP | TCRX | 10% Owner | Dec 19, 2025 | Buy | $0.90 | 80,069 | $71,974.02 | 8,019,148 |
Compare TCRX vs Leading Stocks
See how TCRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TCRX TScan Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.